

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

PROPOSED APPOINTMENT OF AN ADDITIONAL EXECUTIVE DIRECTOR

The board of directors (the “**Board**”) of Alibaba Health Information Technology Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) announces that the Board resolved to nominate Mr. Wang Qiang (“**Mr. Wang**”) to be elected as an executive director of the Company, subject to the approval of the shareholders of the Company (the “**Shareholders**”) at the annual general meeting of the Company to be convened on July 20, 2018 (the “**Annual General Meeting**”).

The biography of Mr. Wang is set out below:

Mr. Wang Qiang, 41, joined the Group as chief financial officer since September 2017, and is responsible for the Group’s financial management, capital markets, internal controls and procurement. He currently serves as a director of certain subsidiaries of the Company and also acts as a consultant to Alibaba Group Holding Limited (the ultimate controlling Shareholder of the Company, and the American depository shares of which are listed on the New York Stock Exchange) and its subsidiaries. Prior to joining the Group, Mr. Wang was the vice president of Intime Retail (Group) Company Limited (“**Intime**”) since January 2014 and chief financial officer of Intime since July 2014, and was responsible for the company’s financial management, cost control, investment development, legal affairs, information management, capital markets and investor relations. He had been assistant to president of Intime since February 2012 and general manager of financial management department of Intime since March 2008, responsible for Intime’s financial management. Prior to joining Intime, he took various financial management positions in Veolia Water, Asia Pacific and ABB China from 1999 to 2008.

Mr. Wang was also a director of Wuhan Department Store Group Co., Ltd. (SZSE: 00501) from December 2013 to June 2018. He graduated from the accounting department of Renmin University of China in 1999 and obtained a bachelor's degree in economics.

As at the date of this announcement, Mr. Wang was interested in 4,000,000 Shares and 1,200,000 Shares, respectively, underlying the options and restricted share units (the “**Share Awards**”) granted to him in accordance with the company's share award scheme adopted at a special general meeting on November 24, 2014 (the “**Share Award Scheme**”), within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed, as at the date of this announcement, Mr. Wang did not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed, Mr. Wang did not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years and did not hold any other position with the Company or other members of the Group.

Subject to the approval by the Shareholders of his appointment as executive director at the Annual General Meeting, Mr. Wang is expected to enter into an appointment letter with the Company in relation to such proposed appointment for a term of one year commencing from the date of the Annual General Meeting. The term of such appointment shall be renewable for a one-year period upon expiry of each term, subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the provisions of the bye-laws of the Company.

In addition to the Share Awards granted to him in accordance with the Share Award Scheme as aforementioned, Mr. Wang is entitled to receive a salary of RMB96,300 per month as chief financial officer of the Group. His remuneration was determined with reference to his experience and prevailing market rates. Mr. Wang will not receive remuneration from the Company for his position as executive director, if such appointment is approved by the Shareholders at the Annual General Meeting.

A circular containing, among other things, the proposed appointment of Mr. Wang as executive director of the Company, together with the notice of the Annual General Meeting will be dispatched to the Shareholders on June 20, 2018.

By Order of the Board
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED
SHEN Difan
Chief Executive Officer and Executive Director

Hong Kong, June 19, 2018

As at the date of this announcement, the Board comprises eight directors, of whom (i) one is an executive Director, namely Mr. SHEN Difan; (ii) four are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei, Mr. KANG Kai and Ms. ZHANG Yu; and (iii) three are independent non-executive Directors, namely Mr. YAN Xuan, Mr. LUO Tong and Mr. WONG King On, Samuel.